Full Press Release Details
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre Treated Metastatic Uveal Melanoma.
IDYA
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre Treated Metastatic Uveal Melanoma
Key Takeaway: IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre Treated Metastatic Uveal Melanoma
Price reaction · baseline $20.95 (2021-12-06 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close
+7.6%
day 1 · peak
+12.4%
day 3
+4.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma